Mga Batayang Estadistika
| CIK | 1534133 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CalciMedica, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
Exhibit 99.1 CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute pancreatitis (AP); conversations continue, with alignment on a pivotal trial anticipated a |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 12, 2025 |
Non-employee Director Compensation Policy, as amended. Exhibit 10.2 CalciMedica, Inc. Non-Employee Director Compensation Policy March 2025 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to CalciMedica, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (as amended |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to s Commission File Number 001-39538 CalciMedi |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025 S-8 POS As filed with the Securities and Exchange Commission on June 27, 2025 Registration No. |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 24, 2025 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 24, 2025 |
CalciMedica, Inc. 2023 Equity Incentive Plan. Exhibit 99.1 APPENDIX A CALCIMEDICA, INC. 2023 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 5, 2023 APPROVED BY THE STOCKHOLDERS: MARCH 15, 2023 AMENDED BY THE BOARD OF DIRECTORS: MARCH 28, 2024 APPROVED BY THE STOCKHOLDERS: AUGUST 27, 2024 AMENDED BY THE BOARD OF DIRECTORS: APRIL 23, 2025 APPROVED BY THE STOCKHOLDERS: JUNE 24, 2025 TABLE OF CONTENTS Page 1. GENERAL A-1 2. SHA |
|
| June 24, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CalciMedica, Inc. |
|
| June 24, 2025 |
As filed with the Securities and Exchange Commission on June 24, 2025 S-8 As filed with the Securities and Exchange Commission on June 24, 2025 Registration No. |
|
| June 9, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| June 6, 2025 |
Letter from Moss Adams LLP to the SEC dated June 6, 2025 EX-16.1 Exhibit 16.1 June 6, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by CalciMedica, Inc. included under Item 4.01 of its Current Report on Form 8-K dated June 3, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained therein. Sincerely |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2025 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 14, 2025 |
Exhibit 99.1 CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Au |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciMedic |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 30, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of |
|
| March 27, 2025 |
Offer Letter between CalciMedica, Inc. and Stephen Bardin, MBA, dated November 7, 2024. Exhibit 10.6 November 6, 2024 Stephen Bardin [***] VIA ELECTRONIC DELIVERY Dear Stephen: Position CalciMedica, Inc. (the “Company”) is pleased to offer you employment with the Company on the terms described below. Your employment with the Company will commence on November 7, 2024 (the “Start Date”) and you will be formally appointed to the role of Chief Financial Officer effective one day followin |
|
| March 27, 2025 |
CalciMedica, Inc. Insider Trading Policy, amended April 2023. Exhibit 19.1 CALCIMEDICA, INC. INSIDER TRADING POLICY Amended April 2023 I. PURPOSE It is illegal for any employee, officer or director of CalciMedica, Inc. (the “Company”) to trade in the securities of the Company while in the possession of material nonpublic information about the Company. It is also illegal for any employee, officer or director of the Company to give material nonpublic informati |
|
| March 27, 2025 |
Offer Letter between CalciMedica, Inc. and Michael Dunn, dated August 29, 2014, as amended. Exhibit 10.4 MICHAEL DUNN - AMENDMENT TO OFFER LETTER This Amendment is entered into as of March 20, 2025 by CalciMedica, Inc. (the “Company”) and Michael J. Dunn (“Employee”) and amends that certain employment Offer Letter from the Company to Employee dated August 29, 2014 (“Offer Letter”). WHEREAS, Employee is currently an executive officer of the Company; WHEREAS, the Board of Directors of the |
|
| March 27, 2025 |
Non-Employee Director Compensation Policy. Exhibit 10.20 CalciMedica, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to CalciMedica, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board |
|
| March 27, 2025 |
Exhibit 10.5 KENNETH STAUDERMAN - AMENDMENT TO EMPLOYMENT OFFER LETTER This Amendment is entered into as of March 20, 2025 by CalciMedica, Inc. (the “Company”) and Kenneth Stauderman (“Employee”) and amends that certain employment Offer Letter from the Company to Employee dated August 29, 2014 (“Offer Letter”). WHEREAS, Employee is currently an executive officer of the Company; WHEREAS, the Board |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39538 CalciMedica, In |
|
| March 27, 2025 |
Exhibit 10.3 SUDARSHAN HEBBAR - AMENDMENT TO EMPLOYMENT OFFER LETTER This Amendment is entered into as of March 20, 2025 by CalciMedica, Inc. (the “Company”) and Sudarshan Hebbar, M.D. (“Employee”) and amends that certain employment Offer Letter from the Company to Employee dated August 24, 2015 (“Offer Letter”). WHEREAS, Employee is currently an executive officer of the Company; WHEREAS, the Boar |
|
| March 27, 2025 |
Exhibit 99.1 CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mor |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 5, 2025 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2025 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 5, 2025 |
Exhibit 10.2 Certain information contained in this document has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Omitted portions are marked with “[***]” in this exhibit. SUPPLEMENT to the Loan and Security Agreement dated as of February 28, 2025 among CALCIMEDICA, INC. (“Borrower”) and AVENUE CAPITAL MANAGEMENT II, L.P., a D |
|
| March 5, 2025 |
Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OPI |
|
| March 5, 2025 |
Exhibit 10.1 Certain information contained in this document has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Omitted portions are marked with “[***]” in this exhibit. LOAN AND SECURITY AGREEMENT Dated as of February 28, 2025 among CALCIMEDICA, INC., a Delaware corporation, as “Borrower”, and AVENUE CAPITAL MANAGEMENT II, |
|
| March 5, 2025 |
Exhibit 99.1 CalciMedica Secures Credit Facility for Up to $32.5 Million $10 million funded at close extends cash runway into mid-2026 LA JOLLA, Calif., Mar. 5, 2025 – CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inf |
|
| March 4, 2025 |
Exhibit 99.1 CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo in subset of patients in CARDEA with AKI LA JOLLA, Calif., Mar. 4, 2025 – CalciMedica I |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2025 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2025 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2024 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| December 20, 2024 |
Up to $4,450,000 of Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-273949 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 18, 2023) Up to $4,450,000 of Shares of Common Stock We previously entered into an at the market offering agreement (the “Offering Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”), relating to shares of our common stock, par value $0.0001 per share, offe |
|
| December 13, 2024 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. |
|
| November 26, 2024 |
Joint Filing Agreement, dated November 25, 2024. EX-99.A 2 d865711dex99a.htm EX-99.A Exhibit A JOINT FILING AGREEMENT Pursuant to Rule 13(d)-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on Schedule 13D is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of the u |
|
| November 26, 2024 |
CALC / CalciMedica, Inc. / Sanderling Venture Partners VI LP - SC 13D Activist Investment SC 13D 1 d865711dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CALCIMEDICA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q 202 (CUSIP Number) Sanderling Venture Partners VI, LP Sanderling Venture Partners VI Co-Investment Fund, L.P. Sanderling Ventures |
|
| November 14, 2024 |
SC 13G/A 1 ea0221047-13ga2soleus3calci.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CALCIMEDICA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) September 30, 2024 (Date of Event Which Requir |
|
| November 14, 2024 |
CALC / CalciMedica, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 38942Q202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 13, 2024 |
Exhibit 99.1 CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in a position to initiate Phase 3 program in 2025 Enrollment ongoing in Phase 2 KOURAGE trial in acute kidney injury (AKI) and in Pha |
|
| November 13, 2024 |
CALC / CalciMedica, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CalciMedica, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 38942Q202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciM |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2024 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| November 6, 2024 |
CALC / CalciMedica, Inc. / Valence Investments SPV VI, LLC - SC 13D/A Activist Investment SC 13D/A 1 d863325dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) CALCIMEDICA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q 202 (CUSIP Number) Valence Investments SPV IV, LLC Valence Investments SPV V, LLC Valence Investments SPV |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2024 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| October 31, 2024 |
Exhibit 1.1 CALCIMEDICA, INC. 2,720,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001) UNDERWRITING AGREEMENT October 30, 2024 October 30, 2024 JonesTrading Institutional Services LLC c/o JonesTrading Institutional Services LLC 325 Hudson Street, 6th Floor New York, New York 10013 Ladies and Gentlemen: CalciMedica, Inc., a Delaware corporation (the “Company”), pursuant to this agreement (this “Agreeme |
|
| October 31, 2024 |
CalciMedica Announces Pricing of Public Offering of Common Stock Exhibit 99.1 CalciMedica Announces Pricing of Public Offering of Common Stock LA JOLLA, Calif., October 30, 2024 /PRNewswire/ — CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (“CRAC”) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, |
|
| October 31, 2024 |
2,720,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-273949 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 18, 2023) 2,720,000 Shares of Common Stock We are offering 2,720,000 shares of our common stock at a purchase price of $3.75 per share. Our common stock is listed on The Nasdaq Capital Market under the symbol “CALC.” The last reported sale price of our common stock on Th |
|
| October 30, 2024 |
CalciMedica Announces Proposed Public Offering of Common Stock Exhibit 99.1 CalciMedica Announces Proposed Public Offering of Common Stock LA JOLLA, Calif., October 30, 2024 /PRNewswire/ — CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (“CRAC”) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, to |
|
| October 30, 2024 |
Exhibit 99.2 Developing Novel Therapies for Acute Inflammatory and Immunologic Diseases October 2024 1 Forward-Looking Statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding CalciMedica’s business strategy and clinical development plans; the design and potential benefits of CalciMedica’s product candidates; CalciMedica’s ongoing |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| October 30, 2024 |
SUBJECT TO COMPLETION, DATED OCTOBER 30, 2024 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-273949 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| October 30, 2024 |
Exhibit 99.1 CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respira |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2024 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 27, 2024 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 27, 2024 |
As filed with the Securities and Exchange Commission on August 27, 2024 S-8 As filed with the Securities and Exchange Commission on August 27, 2024 Registration No. |
|
| August 27, 2024 |
CalciMedica, Inc. 2023 Equity Incentive Plan Exhibit 10.1 CALCIMEDICA, INC. 2023 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 5, 2023 APPROVED BY THE STOCKHOLDERS: MARCH 15, 2023 AMENDED BY THE BOARD OF DIRECTORS: MARCH 28, 2024 APPROVED BY THE STOCKHOLDERS: AUGUST 27, 2024 TABLE OF CONTENTS Page 1. GENERAL 2 2. SHARES SUBJECT TO THE PLAN 2 3. ELIGIBILITY AND LIMITATIONS 3 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AW |
|
| August 27, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CalciMedica, Inc. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciMedica |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 12, 2024 |
Exhibit 4.16 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. CALCIMEDICA, I |
|
| August 12, 2024 |
Exhibit 99.1 CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2 |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 16, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 8, 2024 |
CALC / CalciMedica, Inc. / LYTTON LAURENCE W Passive Investment SC 13G 1 calc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 38942Q202 (CUSIP Number) June 27, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| June 27, 2024 |
Exhibit 99.1 CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patients Statistically significant dose response with up to 61.7% red |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2024 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 27, 2024 |
Exhibit 99.2 Developing Novel Therapies for Acute Inflammatory and Immunologic Diseases CARPO Trial Topline Results June 27, 2024 1 Confidential Forward-Looking Statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding CalciMedica’s business strategy and clinical development plans; the design and potential benefits of CalciMedica’s |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 13, 2024 |
Exhibit 99.1 CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates Last patient enrolled in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); topline data expected in 2Q 2024 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to initiate patient enrollment in 2Q 2024 with data expected in 2025 Collaborators from Cedar |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciMedic |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (AMENDMENT NO. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 10, 2024 |
Letter from Ernst & Young LLP to the SEC dated April 10, 2024 Exhibit 16.1 April 10, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated April 10, 2024, of CalciMedica, Inc. and are in agreement with the statements contained in the second sentence of the first paragraph, and the second, third and fourth paragraphs on page 1 therein. We have no basis to agree or disagree with |
|
| March 29, 2024 |
Up to $17,068,386 of Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-273949 PROSPECTUS SUPPLEMENT (To Prospectus dated August 18, 2023) Up to $17,068,386 of Shares of Common Stock This prospectus supplement amends our prospectus dated August 18, 2023 (the “Prior Prospectus”), filed as part of our registration statement on Form S-3 (File No. 333-273949). This prospectus supplement should be read in conjunction wi |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 28, 2024 |
CalciMedica, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 CalciMedica, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of CalciMedica, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 S-8 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Exhibit 21.1 CalciMedica, Inc. Subsidiaries of the Registrant CalciMedica Subsidiary Inc., a Delaware corporation. RainBio, Inc., a North Carolina corporation. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 28, 2024 |
Exhibit 99.1 CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024 Auxora granted Investigational New Drug clearance by the FDA for Phase 2 trial in severe acute kidney injury (AKI); KOURAGE initiating in 2Q 2024 CRSPA Phase 1/2 trial of Auxora in |
|
| March 28, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CalciMedica, Inc. |
|
| March 28, 2024 |
Description of Registrant’s Common Stock Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2023, CalciMedica, Inc. (the “Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description summarizes the most impo |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39538 CalciMedica, In |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 13, 2024 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| February 13, 2024 |
Exhibit 99.1 Developing Novel Therapies for Acute Inflammatory and Immunologic Diseases February 2024 1 Forward-Looking Statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding CalciMedica’s business strategy and clinical development plans; the design and potential benefits of CalciMedica’s product candidates; CalciMedica’s ongoin |
|
| February 8, 2024 |
SC 13G/A 1 ea193123-13ga1soleuscalci.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) February 5, 2024 (Date of Event Which Requires F |
|
| February 8, 2024 |
CALC / CalciMedica, Inc. / Valence Investments SPV VI, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 7, 2024 |
CALCIMEDICA, INC. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037 CALCIMEDICA, INC. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037 February 7, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Tyler Howes RE: CalciMedica, Inc. Registration Statement on Form S-3 File No. 333-276793 Ladies and Gentlemen: CalciMedica, Inc. (the “Registrant”) hereby requests th |
|
| February 7, 2024 |
CALC / CalciMedica, Inc. / BML Investment Partners, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) December 31, 2023 |
|
| February 5, 2024 |
CALC / CalciMedica, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment SC 13D/A 1 ss2991464sc13da.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* CalciMedica, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 38942Q202 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Tele |
|
| February 5, 2024 |
Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC. EX-99.1 2 ss2991464ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 4 to Schedule 13D, dated February 5, 2024, with respect to the common stock of CalciMedica, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of t |
|
| February 1, 2024 |
CALC / CalciMedica, Inc. / Flynn James E Passive Investment SC 13G 1 e619220sc13g-calcimedica.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* CalciMedica, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 38942Q202 (CUSIP Number) January 23, 202 |
|
| February 1, 2024 |
CALC / CalciMedica, Inc. / Aisling Capital V, LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) January 23, 2024 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to designate the rule pu |
|
| January 31, 2024 |
CALC / CalciMedica, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CalciMedica, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 38942Q202 (CUSIP Number) January 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| January 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CalciMedica, Inc. |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024 Table of Contents As filed with the Securities and Exchange Commission on January 31, 2024 Registration No. |
|
| January 26, 2024 |
CALC / CalciMedica, Inc. / Soleus Capital Master Fund, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 ea192128-13gsoleuscalci.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) January 23, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| January 24, 2024 |
EX-4.3 Exhibit 4.3 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED |
|
| January 24, 2024 |
Form of Tranche B Common Warrant EX-4.2 Exhibit 4.2 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED |
|
| January 24, 2024 |
EX-99.1 Exhibit 99.1 CalciMedica Announces Private Placement of up to Approximately $55 Million $20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million Upfront net proceeds to provide funds to expand Auxora™ clinical development to include planned Phase 2 acute kidney injury (AKI) trial exp |
|
| January 24, 2024 |
Form of Tranche A Common Warrant EX-4.1 Exhibit 4.1 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED |
|
| January 24, 2024 |
Form of Placement Agent Warrant EX-4.4 Exhibit 4.4 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation |
|
| January 24, 2024 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 19, 2024 (the “Effective Date”), among CalciMedica, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and |
|
| January 24, 2024 |
Form of Registration Rights Agreement by and among CalciMedica, Inc. and the persons party thereto EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January [23], 2024, by and between CalciMedica Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securi |
|
| January 22, 2024 |
Exhibit 99.1 CalciMedica Announces Private Placement of up to Approximately $55 Million $20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million Upfront net proceeds to provide funds to expand Auxora™ clinical development to include planned Phase 2 acute kidney injury (AKI) trial expected to |
|
| January 22, 2024 |
Form of Placement Agent Warrant Exhibit 4.4 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD |
|
| January 22, 2024 |
Form of Tranche A Common Warrant Exhibit 4.1 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 22, 2024 |
Form of Registration Rights Agreement by and among CalciMedica, Inc. and the persons party thereto. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January [23], 2024, by and between CalciMedica Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pur |
|
| January 22, 2024 |
Form of Tranche B Common Warrant Exhibit 4.2 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD |
|
| January 22, 2024 |
Exhibit 4.3 THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD |
|
| January 22, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 19, 2024 (the “Effective Date”), among CalciMedica, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and deliver |
|
| November 22, 2023 |
CALC / CalciMedica Inc / Valence Investments SPV VI, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciM |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 CalciMedica, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 9, 2023 |
Exhibit 99.1 CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates Continued expansion of Phase 1/2 CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT); data from initial cohort to be presented at 65th Annual American Society of Hematology (ASH) Meeting & Exposition International expansion of Phase 2b CARPO trial in acute pancreati |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| November 2, 2023 |
Exhibit 99.1 CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition AuxoraTM showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit (ICU) days and eliminated the need for total parenteral nutrition (TPN) LA JOLLA, CA, Nov. 2, 2023 – CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage bi |
|
| August 16, 2023 |
CALCIMEDICA, INC. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037 CALCIMEDICA, INC. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037 August 16, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Jimmy McNamara RE: CalciMedica, Inc. Registration Statement on Form S-3 File No. 333-273949 Ladies and Gentlemen: CalciMedica, Inc. (the “Registrant”) hereby requests |
|
| August 11, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.15 Exhibit 4.15 CALCIMEDICA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF 1 CALCIMEDICA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CALCIMEDICA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing |
|
| August 11, 2023 |
EX-99.1 Exhibit 99.1 BUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates act upon calcium release-activated calcium (“CRAC”) channels, and would constitute a new class of drugs. We are a company |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciMedica |
|
| August 11, 2023 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT August 11, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: CalciMedica, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement |
|
| August 11, 2023 |
Report of Independent Registered Public Accounting Firm EX-99.2 Exhibit 99.2 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of CalciMedica, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of CalciMedica, Inc. (the Company) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, convertible preferred stock and stockhold |
|
| August 11, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.16 CALCIMEDICA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CALCIMEDICA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CALCIMEDICA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the |
|
| August 11, 2023 |
Exhibit 4.11 CALCIMEDICA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section |
|
| August 11, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 11, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 11, 2023 |
Power of Attorney (included on signature page). S-3 Table of Contents As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CalciMedica, Inc. |
|
| August 11, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.14 CALCIMEDICA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CALCIMEDICA, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between CALCIMEDICA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [ |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 10, 2023 |
Exhibit 99.1 CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates International expansion of CARPO, a Phase 2b clinical trial of Auxora in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS), in India Expansion of team with key leadership appointments in regulatory and clinical development Filing of an inv |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 23, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 15, 2023 |
EX-99.1 Exhibit 99.1 CalciMedica Developing First-in-Class Therapies for Acute Inflammatory Diseases with High Unmet Need June 2023 Forward-Looking Statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding CalciMedica’s business strategy and clinical development plans; the design and potential benefits of CalciMedica’s product cand |
|
| June 15, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 14, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CalciMedica, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-2120079 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 505 |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 12, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 12, 2023 |
CalciMedica Announces Relisting on Nasdaq June 12, 2023 11:30 AM EDT EX-99.1 Exhibit 99.1 CalciMedica Announces Relisting on Nasdaq June 12, 2023 11:30 AM EDT LA JOLLA, Calif., June 12, 2023 (GLOBE NEWSWIRE) – CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced that The Nasdaq Stock Market LLC has approved CalciMedi |
|
| May 23, 2023 |
CALC / CalciMedica Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 5)* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) David Clark Elliot Press Deerfiel |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 15, 2023 |
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates EX-99.1 Exhibit 99.1 CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates LA JOLLA, CA, May 15, 2023 – CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended Ma |
|
| May 12, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 CalciMedica, Inc. |
|
| May 12, 2023 |
Exhibit 10.9 CalciMedica, Inc. 2023 Employee Stock Purchase Plan Adopted by the Board of Directors: February 5, 2023 Approved by the Stockholders: March 15, 2023 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to gran |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciMedic |
|
| May 12, 2023 |
Report of Independent Registered Public Accounting Firm EX-99.1 Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of CalciMedica, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of CalciMedica, Inc. (the Company) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, convertible preferred stock and stockhold |
|
| May 12, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EX-99.2 4 d386273dex992.htm EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Merger On November 21, 2022, Graybug Vision, Inc. (“Graybug”) entered into the merger agreement with CalciMedica, Inc. (“CalciMedica”) and Camaro Merger Sub, Inc. (the “merger subsidiary or merger sub”). Upon the terms and subject to the satisfaction of the conditions described in the merge |
|
| May 12, 2023 |
Power of Attorney. Reference is made to the signature page hereto. S-8 As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 26, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 12, 2023 |
CALCIMEDICA, INC. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037 CORRESP CALCIMEDICA, INC. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037 April 12, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Cindy Polynice RE: CalciMedica, Inc. Registration Statement on Form S-3 File No. 333-271115 Ladies and Gentlemen: CalciMedica, Inc. (the “Registrant”) hereby re |
|
| April 4, 2023 |
Form of Warrant to Purchase Shares of Series B Convertible Preferred Stock of CalciMedica, Inc. EX-4.9 Exhibit 4.9 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. CALCIMED |
|
| April 4, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (AMENDMENT NO.1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| April 4, 2023 |
Report of Independent Registered Public Accounting Firm EX-99.1 Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of CalciMedica, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of CalciMedica, Inc. (the Company) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, convertible preferred stock and stockhold |
|
| April 4, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CalciMedica, Inc. |
|
| April 4, 2023 |
As filed with the Securities and Exchange Commission on April 4, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 4, 2023 Registration No. |
|
| April 4, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Merger On November 21, 2022, Graybug Vision, Inc. (“Graybug”) entered into the merger agreement with CalciMedica, Inc. (“CalciMedica”) and Camaro Merger Sub, Inc. (the “merger subsidiary or merger sub”). Upon the terms and subject to the satisfaction of the conditions described in the merger agreement, the merger subs |
|
| March 30, 2023 |
CALC / CalciMedica Inc / Valence Investments SPV VI, LLC - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CALCIMEDICA, INC. |
|
| March 30, 2023 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each |
|
| March 30, 2023 |
EX-99.A 2 d486014dex99a.htm EX-99.A Exhibit A JOINT FILING AGREEMENT Pursuant to Rule 13(d)-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on Schedule 13D is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of the u |
|
| March 30, 2023 |
CALC / CalciMedica Inc / Leerink Revelation Healthcare Fund I, L.p. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* CalciMedica, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 38942Q202 (CUSIP Number) March 20, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| March 28, 2023 |
CALC / CalciMedica Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 4)* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) David Clark Elliot Press Deerfiel |
|
| March 27, 2023 |
CALC / CalciMedica Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 3)* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) David Clark Elliot Press Deerfiel |
|
| March 24, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| March 24, 2023 |
CALC / CalciMedica Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3)* Under the Securities Exchange Act of 1934 CalciMedica, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 38942Q202 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Teleph |
|
| March 22, 2023 |
EX-10.11 22 d485425dex1011.htm EX-10.11 Exhibit 10.11 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as of October 26, 2020 (the “Effective Date”), by and between CalciMedica, Inc., a Delaware corporation, with its principal place of business being 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037 (the “Company”) and Danforth Advisors, LLC, a Massachusett |
|
| March 22, 2023 |
EX-10.7 Exhibit 10.7 Standard Stock Option Grant Package CALCIMEDICA, INC. STOCK OPTION GRANT NOTICE (2023 EQUITY INCENTIVE PLAN) CalciMedica, Inc. (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and |
|
| March 22, 2023 |
Amended and Restated Certificate of Incorporation of the Registrant. EX-3.1 Exhibit 3.1 GRAYBUG VISION, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Graybug Vision Inc., hereby certifies as follows 1. The name of this corporation is “Graybug Vision, Inc.” The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was February 19, 2015 under the name Graybug, Inc. 2. This Amended and Restated Ce |
|
| March 22, 2023 |
EX-10.13 Exhibit 10.13 AMENDMENT TO RESTRICTED STOCK UNIT AWARD AGREEMENT This Amendment to Restricted Stock Unit Award Agreement (the “Amendment”) is made and entered into as of March 20, 2023 by and between Graybug Vision, Inc. (the “Company”) and [ ] (the “Holder”). The Company, Camaro Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”) and CalciMe |
|
| March 22, 2023 |
Offer Letter between CalciMedica, Inc. and Michael Dunn, dated August 29, 2014. Exhibit 10.4 August 29, 2014 Michael Dunn [***] Dear Michael: The purpose of this letter agreement is to confirm the current terms and conditions of your employment with CalciMedica, Inc. (“CalciMedica” or the “Company”), as its Senior Vice President of Corporate Development. This letter agreement is effective as of April 11, 2014 (the “Effective Date”). During your employment term, you will recei |
|
| March 22, 2023 |
EX-4.6 Exhibit 4.6 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. CALCIMED |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2023 Date of Report (Date of earliest event reported) CalciMedica, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 22, 2023 |
EX-10.12 Exhibit 10.12 AMENDMENT TO STOCK OPTION AWARD AGREEMENT This Amendment to Stock Option Award Agreement (the “Amendment”) is made and entered into as of March 20, 2023 (the “Agreement Date”) by and between Graybug Vision, Inc. (the “Company”) and [First Name Last Name] (the “Holder”). The Company, Camaro Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“ |
|
| March 22, 2023 |
Form of Warrant to Purchase Shares of Series D Convertible Preferred Stock of CalciMedica, Inc. EX-4.2 Exhibit 4.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIR |
|
| March 22, 2023 |
EX-99.1 Exhibit 99.1 CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement – CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” – Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 – Phase 2b results in acute pancre |
|
| March 22, 2023 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GRAYBUG VISION, INC., a Delaware corporation; CAMARO MERGER SUB, INC., a Delaware corporation; and CALCIMEDICA, INC., a Delaware corporation Dated as of November 21, 2022 Table of Contents Page SECTION 1. DESCRIPTION OF TRANSACTION 6 1.1 The Merger 6 1.2 Effects of the Merger 6 1.3 Closing; Effective Time 6 1.4 Certificate o |
|
| March 22, 2023 |
CalciMedica, Inc. 2006 Stock Plan and Form of Stock Option Agreement thereunder. EX-10.10 Exhibit 10.10 CALCIMEDICA, INC. AMENDED AND RESTATED 2006 STOCK PLAN (Amended and Restated effective as of August 15, 2007) 1. Purposes of the Plan. The purposes of this Amended and Restated 2006 Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the |
|
| March 22, 2023 |
EX-3.3 Exhibit 3.3 CERTIFICATE OF MERGER MERGING CAMARO MERGER SUB, INC., A DELAWARE CORPORATION WITH AND INTO CALCIMEDICA SUBSIDIARY, INC., A DELAWARE CORPORATION Pursuant to Title 8, Section 251 of the General Corporation Law of the State of Delaware CalciMedica Subsidiary, Inc., a Delaware corporation (the “Company”), does hereby certify as follows: FIRST: Each of the constituent corporations ( |
|
| March 22, 2023 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GRAYBUG VISION, INC. GRAYBUG VISION, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: The name of the Corporation is Graybug Vision, Inc. SECOND: The date on which the Certifi |
|
| March 22, 2023 |
EX-4.1 Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of November 21, 2022 by and among CalciMedica, Inc., a Delaware corporation, and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Company and the Purchasers are parties to a Securities Purchase Agreement, dated as of |
|
| March 22, 2023 |
EX-4.3 Exhibit 4.3 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. CALCIMED |
|
| March 22, 2023 |
CalciMedica, Inc. 2023 Employee Stock Purchase Plan. EX-10.9 20 d485425dex109.htm EX-10.9 Exhibit 10.9 CALCIMEDICA, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 5, 2023 APPROVED BY THE STOCKHOLDERS: [ ] 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan p |
|
| March 22, 2023 |
Exhibit 10.8 CALCIMEDICA, INC. RSU AWARD GRANT NOTICE (2023 EQUITY INCENTIVE PLAN) CalciMedica, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2023 Equi |
|
| March 22, 2023 |
CalciMedica, Inc. 2023 Equity Incentive Plan. EX-10.6 Exhibit 10.6 CALCIMEDICA, INC. 2023 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 5, 2023 APPROVED BY THE STOCKHOLDERS: March 15, 2023 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 5 6. ADJUSTMENTS UPON CHANGES IN C |
|
| March 22, 2023 |
Offer Letter between CalciMedica, Inc. and Eric Roberts, dated May 20, 2020. EX-10.2 Exhibit 10.2 May 20, 2020 Eric Roberts [***] Dear Mr. Roberts: We are pleased that the stockholders of CalciMedica, Inc. (the “Company”) have designated you as a member of the Company’s Board of Directors (the “Board”) to serve until your successor is duly appointed or your earlier resignation or removal. You shall also serve as the Vice Chairman of the Board and the Chairman of the Strate |
|
| March 22, 2023 |
Offer Letter between CalciMedica, Inc. and A. Rachel Leheny, Ph.D., dated May 20, 2020. Exhibit 10.1 May 20, 2020 Ann Rachel Leheny, Ph.D. [***] Dear Dr. Leheny: CalciMedica, Inc. (the “Company”) is pleased to offer you employment with the Company on the terms described below. Your position will be that of the Company’s Chief Executive Officer. This is a position of full-time employment. You will report to the Company’s Board of Directors (the “Board”) and will have such duties and r |
|
| March 22, 2023 |
Offer Letter between CalciMedica, Inc. and Kenneth A. Stauderman, Ph.D., dated August 29, 2014. EX-10.5 Exhibit 10.5 29 August 2014 Dr. Kenneth A. Stauderman [***] Dear Ken: The purpose of this letter agreement is to confirm the current terms and conditions of your employment with CalciMedica, Inc. (“CalciMedica” or the “Company”), as its Senior Vice President of Research and Development. This letter agreement is effective as of April 11, 2014 (the “Effective Date”). During your employment t |
|
| March 22, 2023 |
EX-4.5 Exhibit 4.5 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGE OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. CALCIMEDI |
|
| March 22, 2023 |
EX-4.4 Exhibit 4.4 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. CALCIMED |
|
| March 22, 2023 |
Offer Letter between CalciMedica, Inc. and Sudarshan Hebbar, M.D., dated August 24, 2015. EX-10.3 Exhibit 10.3 505 Coast Blvd. South, Suite 202 La Jolla, CA 92037 T. 858-952-5500 August 24, 2015 Sudarshan Hebbar, MD [***] Dear Sudarshan: We are pleased to offer you the position of Senior Vice President, Clinical Development with CalciMedica, Inc. (“CalciMedica” or the “Company”) beginning November 9, 2015, or such other date as we shall mutually agree, contingent on both your and the C |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Graybug Vision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 9, 2023 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39538 GRAYBUG VISIO |
|
| March 9, 2023 |
Separation Agreement, dated February 28, 2023, between the Registrant and Parisa Zamiri. Exhibit 10.17 February 28, 2023 Parisa Zamiri Via email Re: Terms of Separation Dear Parisa: This letter confirms the agreement (“Agreement”) between you and Graybug Vision, Inc. (the “Company”) concerning the terms of your separation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue. 1. Separation Date: Your employment is b |
|
| March 3, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or or |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organizati |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organizati |
|
| February 16, 2023 |
EX-2.1 Exhibit 2.1 FIRST AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This First Amendment (this “Amendment”) to the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of November 21, 2022, by and among GRAYBUG VISION, INC., a Delaware corporation (“Parent”), CAMARO MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“ |
|
| February 16, 2023 |
EX-99.1 Exhibit 99.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”) is made as of February 10, 2023 (the “Effective Date”), by and between CALCIMEDICA, INC., a Delaware corporation (the “Company”), and GRAYBUG VISION, INC., a Delaware corporation (“Purchaser”). Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in that certain Agreem |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organizati |
|
| February 13, 2023 |
GRAY / Graybug Vision Inc / AFFAMED PROJECT Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* GRAYBUG VISION, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 13, 2023 |
Exhibit 99.A Exhibit A Joint Filing Agreement The undersigned agree that the foregoing Statement on Schedule 13G (including any and all amendments thereto) is being filed with the Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the Act and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. Dated: F |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2023 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organizatio |
|
| February 9, 2023 |
DEFM14A 1 d192607ddefm14a.htm DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| February 8, 2023 |
GRAY / Graybug Vision Inc / BML Investment Partners, L.P. - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Graybug Vision, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q103 (CUSIP Number) Calendar Year 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 3) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| February 6, 2023 |
CORRESP 1 filename1.htm 555 California Street 12th Floor San Francisco, CA 94104 415.875.2300 Fenwick.com Julia Forbess [email protected] | 415.875.2420 February 6, 2023 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Ibolya Ignat Daniel Gordon Daniel Crawford Tim Bu |
|
| January 31, 2023 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 31, 2023 |
Julia Forbess [email protected] | 415.875.2420 January 31, 2023 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Ibolya Ignat Daniel Gordon Daniel Crawford Tim Buchmiller Re: Graybug Vision, Inc. Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A Filed Jan |
|
| January 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| January 20, 2023 |
555 California Street 12th Floor San Francisco, CA 94104 415.875.2300 Fenwick.com Julia Forbess [email protected] | 415.875.2420 January 20, 2023 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Ibolya Ignat Daniel Gordon Daniel Crawford Tim Buchmiller Re: Graybug Vis |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 GRAYBUG VISION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 14, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Graybug Vision, Inc. |
|
| December 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| December 1, 2022 |
GRAY / Graybug Vision Inc / BML Investment Partners, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Graybug Vision, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q103 (CUSIP Number) November 22, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 23, 2022 |
GRAY / Graybug Vision Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 2)* Graybug Vision, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q103 (CUSIP Number) David Clark Elliot Press Deerf |
|
| November 22, 2022 |
DEFA14A 1 d417403ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other juris |
|
| November 22, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or or |
|
| November 22, 2022 |
Graybug and CalciMedica Enter into Definitive Merger Agreement EX-99.1 6 d403773dex991.htm EX-99.1 Exhibit 99.1 Graybug and CalciMedica Enter into Definitive Merger Agreement • Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases • Combined company is expected to be funded with cash and cash equivalents of approximate |
|
| November 22, 2022 |
Exhibit 99.1 [OPERATOR]: Ladies and gentlemen, thank you for standing by and welcome to the Graybug and CalciMedica Merger Announcement call. I would now like to turn the call over to Fred Guerard, Chief Executive Officer of Graybug. [FRED GUERARD]: Thank you for joining us today. I?m Fred Guerard, Chief Executive Officer of Graybug Vision, and I am joined by Rachel Leheny, Chief Executive Officer |
|
| November 22, 2022 |
Form of CalciMedica, Inc. Support Agreement, dated November 21, 2022 EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of November 21, 2022, by and between GRAYBUG VISION, INC., a Delaware corporation (“Parent”), and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares, $0.001 par value per share (“Company Shares”), of CALCIMEDIC |
|
| November 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organizati |
|
| November 22, 2022 |
Form of Graybug Vision, Inc. Support Agreement, dated November 21, 2022 EX-10.2 Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of November 21, 2022, by and between CALCIMEDICA, INC., a Delaware corporation (the “Company”), and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of Common Stock, $0.0001 par value per share (“Parent Share |
|
| November 22, 2022 |
Form of Lock-Up Agreement, dated November 21, 2022 EX-10.3 Exhibit 10.3 Lock-Up Agreement November 21, 2022 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) GRAYBUG VISION, INC., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022 (the “Merger Agreement”), with CALCIMEDICA, INC., a Delaware corporation (the “Company”) and CAMARO MERGER |
|
| November 22, 2022 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GRAYBUG VISION, INC., a Delaware corporation; CAMARO MERGER SUB, INC., a Delaware corporation; and CALCIMEDICA, INC., a Delaware corporation Dated as of November 21, 2022 Table of Contents Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organizati |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 GRAYBU |
|
| November 10, 2022 |
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022 EX-99.1 2 d407208dex991.htm EX-99.1 Exhibit 99.1 Graybug Vision, Inc. 203 Redwood Shores Parkway Suite 620 Redwood City, CA 94065 www.graybug.vision Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022 REDWOOD CITY, Calif., November 10, 2022 - Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focu |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organizati |
|
| August 23, 2022 |
Material Impairments, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 (August 18, 2022) GRAYBUG VISION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporati |
|
| August 19, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Graybug Vision, Inc. |
|
| August 19, 2022 |
As filed with the Securities and Exchange Commission on August 19, 2022 As filed with the Securities and Exchange Commission on August 19, 2022 Registration No. |
|
| August 19, 2022 |
Amended and Restated 2020 Equity Incentive Plan and forms of award agreements thereunder Exhibit 99.1 GRAYBUG VISION, INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN As amended and restated June 2, 2022 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by of |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 GRAYBUG VIS |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 001-39538 (Commissi |
|
| August 11, 2022 |
Graybug Vision, Inc. 6411 Beckley Street Suite North 200 (N200) Baltimore, MD 21224 www.graybug.vision Exhibit 99.1 Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments BALTIMORE, August 11, 2022 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for |
|
| June 21, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 GRAYBUG VISION, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39538 45-2120079 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 GRAYBUG VISION, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organization) ( |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 GRAYBUG VI |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Graybug Vision, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39538 45-2120079 (State or other jurisdiction of incorporation or organization) ( |
|
| May 10, 2022 |
Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments Graybug Vision, Inc. 6411 Beckley Street Suite North 200 (N200) Baltimore, MD 21224 www.graybug.vision Exhibit 99.1 Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments BALTIMORE, May 10, 2022 - Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided a |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
